Serum markers may distinguish biliary atresia from other forms of neonatal cholestasis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 50, Issue 4, 2010, Pages 411-416

  Wang, Hongtao ^a   Malone, James P ^a   Gilmore, Petra Erdmann ^a   Davis, Alan E ^a   Magee, John C ^b   Townsend, R Reid ^a   Heuckeroth, Robert O ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biliary atresia; Biomarker; Neonatal cholestasis; Proteomics

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; FETUIN A; MANNOSE BINDING LECTIN; PREALBUMIN; PROTEOHEPARAN SULFATE; SERUM AMYLOID P; VITAMIN D BINDING PROTEIN;

ARTICLE; BILE DUCT ATRESIA; CHOLESTASIS; CLINICAL ARTICLE; FEMALE; HUMAN; INFANT; MALE; NEWBORN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SERUM; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BILIARY ATRESIA; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHILD, PRESCHOOL; CHOLESTASIS; DIAGNOSIS, DIFFERENTIAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MALE; TANDEM MASS SPECTROMETRY;

EID: 77950235651     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181cb42ee     Document Type: Article

References (41)

1. De Carvalho E, Ivantes CA, Bezerra JA. Extrahepatic biliary atresia: current concepts and future directions. J Pediatr (Rio J) 2007;83:105-120
2. Bassett MD, Murray KF. Biliary atresia: recent progress. J Clin Gastroenterol 2008;42:720-729
3. Sokol RJ, Mack C, Narkewicz MR, Karrer FM. Pathogenesis and outcome of biliary atresia: current concepts. J Pediatr Gastroenterol Nutr 2003;37:4-21.
4. Sokol RJ, Shepherd RW, Superina R, et al. Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology 2007;46:566-581
5. Wadhwani SI, Turmelle YP, Nagy R, et al. Prolonged neonatal jaundice and the diagnosis of biliary atresia: a single-center analysis of trends in age at diagnosis and outcomes. Pediatrics 2008;121:e1438-40.
6. Chakravarti B, Gallagher SR, Chakravarti DN. Difference gel electrophoresis (DIGE) using CyDye DIGE fluor minimal dyes. Curr Protoc Mol Biol 2005;Chapter 10:Unit 10.23.
7. Maurya P, Meleady P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res 2007;27:1247-1255
8. Hoofnagle JH. Biliary Atresia Research Consortium (BARC). Hepatology 2004;39:891.
9. Bredemeyer AJ, Lewis RM, Malone JP, et al. A proteomic approach for the discovery of protease substrates. Proc Natl Acad Sci U S A 2004; 101:11785-11790
10. Friedman J. Regularized discriminant analysis. J Am Stat Assoc 1989;84:165-175
11. Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 2000;284:876-878
12. Lee CW, Lin MY, Lee WC, et al. Characterization of plasma proteome in biliary atresia. Clin Chim Acta 2007;375:104-109
13. Seidel D. Lipoproteins in liver disease. J Clin Chem Clin Biochem 1987;25:541-551
14. Coulhon MP, Tallet F, Yonger J, Agneray J, Raichvarg D. Changes in human high density lipoproteins in patients with extra-hepatic biliary obstruction. Clin Chim Acta 1985;145:163-172
15. Danielsson B, Ekman R, Johansson BG, Nilsson-Ehle P, Petersson BG. Lipoproteins in plasma from patients with low LCAT activity due to biliary obstruction. Scand J Clin Lab Invest Suppl 1978;150:214-217
16. Allan CM, Taylor S, Taylor JM. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. J Biol Chem 1997;272:29113-29119
17. Kast HR, Nguyen CM, Sinal CJ, et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol 2001;15:1720-1728
18. Li J, Pircher PC, Schulman IG, Westin SK. Regulation of complement C3 expression by the bile acid receptor FXR. J Biol Chem 2005; 280:7427-7434
19. Tazawa Y, Yamada M, Nakagawa M, et al. Significance of serum lipoprotein-X and gammaglutamyltranspeptidase in the diagnosis of biliary atresia. A preliminary study in 27 cholestatic young infants. Eur J Pediatr 1986;145:54-57
20. Miller JP. Dyslipoproteinaemia of liver disease. Baillieres Clin Endocrinol Metab 1990;4:807-832
21. Felker TE, Hamilton RL, Havel RJ. Secretion of lipoprotein-X by perfused livers of rats with cholestasis. Proc Natl Acad Sci U S A 1978;75:3459-3463
22. Albers JJ, Lin J, Roberts GP. Effect of human plasma apolipoproteins on the activity of purified lecithin: cholesterol acyltransferase. Artery 1979;5:61-75.
23. Narayanaswamy B, Gonde C, Tredger JM, et al. Serial circulating markers of inflammation in biliary atresia-evolution of the postoperative inflammatory process. Hepatology 2007;46:180-187
24. Mack CL, Tucker RM, Sokol RJ, et al. Biliary atresia is associated with CD4+ Th1 cell-mediated portal tract inflammation. Pediatr Res 2004;56:79-87.
25. Bezerra JA, Tiao G, Ryckman FC, et al. Genetic induction of proinflammatory immunity in children with biliary atresia. Lancet 2002;360: 1653-1659
26. Potter BJ, Elias E, Fayers PM, Jones EA. Profiles of serum complement in patients with hepatobiliary diseases. Digestion 1978;18:371-383
27. Potter BJ, Trueman AM, Jones EA. Serum complement in chronic liver disease. Gut 1973;14:451-456
28. Thompson RA, Carter R, Stokes RP, Geddes AM, Goodall JA. Serum immunoglobulins, complement component levels and autoantibodies in liver disease. Clin Exp Immunol 1973;14:335-346
29. Gardinali M, Conciato L, Cafaro C, et al. Complement system is not activated in primary biliary cirrhosis. Clin Immunol Immunopathol 1998;87:297-303.
30. Lindgren S, Laurell AB, Eriksson S. Complement components and activation in primary biliary cirrhosis. Hepatology 1984;4:9-14.
31. Bezerra JA. The next challenge in pediatric cholestasis: deciphering the pathogenesis of biliary atresia. J Pediatr Gastroenterol Nutr 2006;43 (suppl 1):S23-9.
32. Sellar GC, Keane J, Mehdi H, et al. Characterization and acute phase modulation of canine apolipoprotein H (beta 2-glycoprotein I). Biochem Biophys Res Commun 1993;191:1288-1293
33. Mehdi H, Nunn M, Steel DM, et al. Nucleotide sequence and expression of the human gene encoding apolipoprotein H (beta 2-glycoprotein I). Gene 1991;108:293-298
34. Ando Y. Immunological and serological laboratory tests: transthyretin. Rinsho Byori 2005;53:554-557
35. Lo WK. Serum parameters, inflammation, renal function and patient outcome. Contrib Nephrol 2006;150:152-155
36. Imamine T, Okuno M, Moriwaki H, et al. Impaired synthesis of retinolbinding protein and transthyretin in rat liver with bile duct obstruction. Dig Dis Sci 1996;41:1038-1042
37. Fuhrman MP, Charney P, Mueller CM. Hepatic proteins and nutrition assessment. J Am Diet Assoc 2004;104:1258-1264
38. Jack DL, Turner MW. Anti-microbial activities of mannose-binding lectin. Biochem Soc Trans 2003;31 (Pt 4):753-757
39. Turner MW, Hamvas RM. Mannose-binding lectin: structure, function, genetics and disease associations. Rev Immunogenet 2000;2:305-322
40. Bijl M, Bootsma H, Van Der Geld Y, et al. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Ann Rheum Dis 2004;63:831-835
41. Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C. Repression of farnesoid X receptor during the acute phase response. J Biol Chem 2003;278:8988-8995